MoonLake Immunotherapeutics (MLTX) Invested Capital (2020 - 2026)

MoonLake Immunotherapeutics' Invested Capital history runs 7 years deep, the most recent figure standing at $353.0 million for Q1 2026.

• In Q1 2026, Invested Capital fell 27.3% year-over-year to $353.0 million; the TTM figure through Mar 2026 stood at $353.0 million (down 27.3% YoY), while the FY2025 annual figure was $378.6 million, down 15.27% from the prior year.
• Invested Capital was $353.0 million for Q1 2026 at MoonLake Immunotherapeutics, down from $378.6 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $552.4 million in Q1 2024 to a low of -$25.3 million in Q1 2022.
• Historically, Invested Capital has averaged $342.2 million across 5 years, with a median of $431.3 million in 2025.
• Biggest YoY gain for Invested Capital was 11310.99% in 2022; the steepest drop was 10205.8% in 2022.
• A 5-year view of Invested Capital shows it stood at $68.8 million in 2022, then jumped by 646.71% to $513.5 million in 2023, then fell by 12.98% to $446.8 million in 2024, then decreased by 15.27% to $378.6 million in 2025, then retreated by 6.75% to $353.0 million in 2026.
• The last three Invested Capital figures came in at $353.0 million (Q1 2026), $378.6 million (Q4 2025), and $362.6 million (Q3 2025), per Business Quant data.